peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

HBP-assay website launched

14 Nov 2012, 15:00
Regulatory information

A dedicated product website for Heparin Binding Protein as biomarker for diagnosis of severe sepsis has been launched by Hansa Medical’s development partner Axis-Shield Diagnostics:

The goal is to launch a CE-marked HBP-assay in December 2012. Currently, the result from an international pivotal multicentre trial is being evaluated.

Sepsis is the body's systemic inflammatory response to infection and can progress to severe sepsis, septic shock and ultimately multiple organ failure. Early diagnosis and appropriate treatment of severe sepsis is vital to improve the patient's chance of survival. Heparin Binding Protein is a new marker that has been shown to be useful in identifying patients on admission to the Emergency Department who are at risk of developing severe sepsis with circulatory failure.

In 2009, Hansa Medical entered a collaboration and license agreement with Axis-Shield Diagnostics to further develop the Hansa Medical prototype HBP-assay (HMD-301) and subsequently launch a commercial assay. Hansa Medical estimates the market for diagnosis and prognosis of severe sepsis to at least 3 million analyses per year in EU, Japan and the US.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoS and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.